Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$258K Sell
9,174
-136
-1% -$3.62K 0.13% 156
2025
Q4
$232K Sell
9,310
-1,153
-11% -$29.1K 0.12% 164
2025
Q3
$267K Sell
10,463
-1,000
-9% -$24.7K 0.14% 140
2025
Q2
$278K Sell
11,463
-460
-4% -$10.7K 0.18% 125
2025
Q1
$302K Sell
11,923
-1,515
-11% -$39.6K 0.2% 116
2024
Q4
$357K Sell
13,438
-10,691
-44% -$290K 0.25% 98
2024
Q3
$698K Sell
24,129
-1,276
-5% -$37.2K 0.44% 70
2024
Q2
$711K Buy
25,405
+7,164
+39% +$197K 0.5% 63
2024
Q1
$506K Sell
18,241
-1,718
-9% -$47.7K 0.36% 84
2023
Q4
$575K Sell
19,959
-3,910
-16% -$118K 0.45% 73
2023
Q3
$792K Sell
23,869
-335
-1% -$11.8K 0.69% 40
2023
Q2
$888K Sell
24,204
-128
-0.5% -$4.98K 0.75% 36
2023
Q1
$993K Sell
24,332
-2,145
-8% -$92.6K 0.88% 29
2022
Q4
$1.36M Buy
26,477
+1,151
+5% +$55.2K 1.3% 21
2022
Q3
$1.11M Buy
25,326
+860
+4% +$41.8K 1.23% 21
2022
Q2
$1.28M Buy
24,466
+1,650
+7% +$84.1K 1.43% 18
2022
Q1
$1.18M Sell
22,816
-957
-4% -$49.7K 1.17% 22
2021
Q4
$1.4M Buy
+23,773
New +$1.18M 1.42% 16

Other funds holding PFE

Carson Advisory's PFE Position: Q1 2026 in Review

Carson Advisory reduced its Pfizer (PFE) stake by 1.5% in Q1 2026, selling an estimated $3.62K and leaving 9,174 shares worth $258K. The position accounts for 0.13% of the portfolio, ranked #156.

Carson Advisory first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.4M in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Carson Advisory held 9,174 shares of Pfizer worth $258K as of Q1 2026.
  • Carson Advisory sold 136 Pfizer shares in Q1 2026, an estimated $3.62K.
  • Pfizer made up 0.13% of Carson Advisory's portfolio in Q1 2026, its #156 holding.
  • Carson Advisory first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • Carson Advisory's Pfizer position peaked at $1.4M in Q4 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Carson Advisory's 13F filing for Q1 2026, filed 7 May 2026.